NASDAQ:HCWB HCW Biologics (HCWB) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free HCWB Stock Alerts $1.32 -0.06 (-4.13%) (As of 05:13 PM ET) Add Compare Share Share Today's Range$1.32▼$1.4050-Day Range$1.18▼$1.7752-Week Range$0.91▼$2.32Volume4,298 shsAverage Volume14,391 shsMarket Capitalization$49.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get HCW Biologics alerts: Email Address Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About HCW Biologics Stock (NASDAQ:HCWB)HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Read More HCWB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HCWB Stock News HeadlinesApril 24, 2024 | americanbankingnews.comHCW Biologics (NASDAQ:HCWB) Stock Price Down 1.6%April 2, 2024 | investorplace.comHCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023May 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).April 1, 2024 | globenewswire.comHCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business HighlightsFebruary 24, 2024 | finance.yahoo.comRebecca Byam Bought 122% More Shares In HCW BiologicsJanuary 25, 2024 | finance.yahoo.comSeveral Insiders Invested In HCW Biologics Flagging Positive NewsNovember 17, 2023 | markets.businessinsider.comHCW Biologics Receives Buy Rating: Strong Financial Position and Promising Clinical Data Validate Investment OpportunityNovember 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: HCW Biologics (HCWB), Urogen Pharma (URGN)May 2, 2024 | Stansberry Research (Ad)$5,000 Gold?Former Wall Street Banker Reveals Mysterious Gold Leverage As gold continues to soar, this ex-Goldman Sachs VP says DON'T buy bullion or mining stocks. Instead, he's just shared a "gold bank" that uses about $10 of your money to harness the power of two ounces of pure gold (worth about $4,200 right now).November 14, 2023 | finanznachrichten.deHCW Biologics, Inc: HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business HighlightsNovember 14, 2023 | msn.comHCW Biologics GAAP EPS of -$0.14, revenue of $174.77MNovember 14, 2023 | finance.yahoo.comHCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business HighlightsNovember 11, 2023 | morningstar.comADMA Biologics Inc ADMANovember 11, 2023 | morningstar.comHCW Biologics Inc HCWBNovember 11, 2023 | markets.businessinsider.comPromising Phase 1 Results and Potential Synergies with PD-1 Inhibitors Bolster Buy Rating for HCW BiologicsNovember 8, 2023 | finance.yahoo.comInvestigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual MeetingNovember 6, 2023 | finance.yahoo.comSamsung Biologics and Kurma Partners announce strategic partnership for development and manufacturing of biologics for Kurma's portfolio companiesNovember 1, 2023 | finance.yahoo.comMasonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual MeetingSeptember 21, 2023 | seekingalpha.comHCW Biologics director Gary Winer buys shares worth $3.3k - filingSeptember 16, 2023 | finance.yahoo.comInsider Buying: CFO Rebecca Byam Acquires 5,000 Shares of HCW Biologics IncSeptember 9, 2023 | finance.yahoo.comInsider Buying: CFO Rebecca Byam Acquires 10,000 Shares of HCW Biologics IncSeptember 6, 2023 | finance.yahoo.comHCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023August 18, 2023 | finance.yahoo.comInsider Stock Buying Reaches US$845k On HCW BiologicsAugust 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Cochlear Limited (OtherCHEOF)August 11, 2023 | finanznachrichten.deHCW Biologics, Inc: HCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: HCW Biologics (HCWB) and Arrowhead Pharmaceuticals (ARWR)August 11, 2023 | finance.yahoo.comHCW Biologics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsSee More Headlines Receive HCWB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HCW Biologics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/02/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HCWB CUSIPN/A CIK1828673 Webwww.hcwbiologics.com Phone954-842-2024Fax954-842-2037Employees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,990,000.00 Net Margins-879.49% Pretax Margin-879.45% Return on Equity-101.47% Return on Assets-67.94% Debt Debt-to-Equity Ratio0.47 Current Ratio0.73 Quick Ratio0.73 Sales & Book Value Annual Sales$2.84 million Price / Sales17.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.37 per share Price / Book3.57Miscellaneous Outstanding Shares37,820,000Free Float20,689,000Market Cap$49.92 million OptionableNot Optionable Beta1.04 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Hing C. Wong Ph.D. (Age 70)Founder, CEO, Director & Secretary Comp: $421.05kMs. Rebecca Byam CPA (Age 68)M.B.A., Chief Financial Officer Comp: $297.08kDr. Peter Rhode Ph.D. (Age 66)Chief Scientific Officer & VP of Clinical Operations Comp: $248.57kMs. Nicole Valdivieso Esq.Vice President of Legal AffairsMs. Raquel Diaz M.S.Director of Human ResourcesMr. Lee D. Flowers (Age 78)Senior Vice President of Business Development More ExecutivesKey CompetitorsEagle PharmaceuticalsNASDAQ:EGRXEquilliumNASDAQ:EQBioLineRxNASDAQ:BLRXLantern PharmaNASDAQ:LTRNCleneNASDAQ:CLNNView All CompetitorsInsiders & InstitutionsPullen Investment Management LLCBought 85,116 shares on 5/2/2024Ownership: 0.225%Avantax Planning Partners Inc.Bought 179,541 shares on 2/9/2024Ownership: 0.499%Hing C WongBought 1,800 shares on 9/14/2023Total: $3,744.00 ($2.08/share)Rebecca ByamBought 5,000 shares on 9/13/2023Total: $10,500.00 ($2.10/share)Gary M WinerBought 546 shares on 9/13/2023Total: $1,119.30 ($2.05/share)View All Insider TransactionsView All Institutional Transactions HCWB Stock Analysis - Frequently Asked Questions How have HCWB shares performed in 2024? HCW Biologics' stock was trading at $1.2250 at the beginning of 2024. Since then, HCWB stock has increased by 7.8% and is now trading at $1.32. View the best growth stocks for 2024 here. Are investors shorting HCW Biologics? HCW Biologics saw a drop in short interest in April. As of April 15th, there was short interest totaling 7,600 shares, a drop of 52.2% from the March 31st total of 15,900 shares. Based on an average daily trading volume, of 15,500 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company's stock are short sold. View HCW Biologics' Short Interest. When is HCW Biologics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our HCWB earnings forecast. How were HCW Biologics' earnings last quarter? HCW Biologics Inc. (NASDAQ:HCWB) released its earnings results on Monday, April, 1st. The company reported ($0.30) EPS for the quarter. The company earned $1.32 million during the quarter. HCW Biologics had a negative net margin of 879.49% and a negative trailing twelve-month return on equity of 101.47%. When did HCW Biologics IPO? HCW Biologics (HCWB) raised $45 million in an initial public offering (IPO) on Tuesday, July 20th 2021. The company issued 5,600,000 shares at $8.00 per share. EF Hutton served as the underwriter for the IPO and Revere Securities was co-manager. Who are HCW Biologics' major shareholders? HCW Biologics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pullen Investment Management LLC (0.23%). Insiders that own company stock include Gary M Winer, Hing C Wong, Jin-An Jiao, Lee Flowers, Rebecca Byam and Rick S Greene. View institutional ownership trends. How do I buy shares of HCW Biologics? Shares of HCWB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HCWB) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingYour bank is lying to you.MyBankTrackerA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsA once-in-a-century investment opportunityStansberry ResearchTrump just won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
